Background: Sunitinib is an oral multitargeted tyrosine kinase receptor inhibitor (MTKI) used for the treatment of renal cell carcinoma. These small-molecule agents inhibit signaling through receptor tyrosine kinases such as vascular endothelial growth factor receptor, platelet-derived growth factor receptor and cytokine stem cell factor receptor, among others. Although the development of these novel molecular-targeted agents represents a substantial advance in the treatment of metastatic cancer, the spectrum of their adverse effects may be broader than initially predicted. Method: We performed a retrospective chart review of patients who had received sunitinib and developed renal insufficiency. Results: We describe 4 patients with renal cell carcinoma and 1 patient with transitional cell carcinoma treated with sunitinib who experienced various degrees of nephrotoxicity including hypertension, proteinuria, thrombotic microangiopathy, and acute and chronic kidney injury which resolved upon cessation of MTKI. Conclusions: Nephrologists and oncologists should be aware of the potential for toxic renal effects, and we recommend guidelines for early recognition and treatment of these conditions in patients receiving MTKI.

Keywords:
Sunitinib, Tyrosine kinase inhibitors, Chemotherapy, Renal failure, Acute kidney injury, Thrombotic microangiopathy, Nephrotoxicity
1.
Kroog GS, Motzer RJ: Systemic therapy for metastatic renal cell carcinoma. Urol Clin North Am 2008;35:687–701, ix.
2.
Motzer RJ, Rini BI, Bukowski RM, et al: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516–2524.
3.
Rock EP, Goodman V, Jiang JX, et al: Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007;12:107–113.
4.
Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584–3590.
5.
Obhrai JS, Patel TV, Humphreys BD: The case/progressive hypertension and proteinuria on anti-angiogenic therapy. Kidney Int 2008;74:685–686.
6.
Patel TV, Morgan JA, Demetri GD, et al: A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 2008;100:282–284.
7.
Jain R, Mathew P, Wood CG, Tannir NM: Sunitinib-induced acute hemolysis without hypertension: a case report. Clin Genitourin Cancer 2008;6:122–123.
8.
Bollee G, Patey N, Cazajous G, et al: Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant 2009;24:682–685.
9.
Frangie C, Lefaucheur C, Medioni J, Jacquot C, Hill GS, Nochy D: Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 2007;8:177–178.
10.
Kapiteijn E, Brand A, Kroep J, Gelderblom H: Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol 2007;18:1745–1747.
11.
Levey SA, Bajwa RS, Picken MM, Clark JI, Barton K, Leehey DJ: Thrombotic microangiopathy associated with sunitinib, a VEGF inhibitor, in a patient with factor V Leiden mutation. NDT Plus 2008;3:154–156.
12.
Choi MK, Hong JY, Jang JH, Lim HY: TTP-HUS associated with sunitinib. Cancer Res Treat 2008;40:211–213.
13.
Khurana A: Allergic interstitial nephritis possibly related to sunitinib use. Am J Geriatr Pharmacother 2007;5:341–34.
14.
Izzedine H, Brocheriou I, Rixe O, Deray G: Interstitial nephritis in a patient taking sorafenib. Nephrol Dial Transplant 2007;22:2411.
15.
Winn SK, Ellis S, Savage P, Sampson S, Marsh JE: Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect? Nephrol Dial Transplant 2009;24:673–675.
16.
Soria JC, Massard C, Izzedine H: From theoretical synergy to clinical supra-additive toxicity. J Clin Oncol 2009;27:1359–1361.
17.
Feldman DR, Baum MS, Ginsberg MS, et al: Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:1432–1439.
18.
Rolleman EJ, Weening J, Betjes MG: Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma. Nephrol Dial Transplant 2009;24:2002–2003.
19.
Leung N, Saucier NA, Zeldenrust SR, Gunderson HD, Cornell LD: Acute renal failure after treatment with sunitinib in a patient with multiple myeloma. NDT Plus 2009;2:292–294.
20.
Gurevich F, Perazella MA: Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med 2009;122:322–328.
21.
Eremina V, Sood M, Haigh J, et al: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003;111:707–716.
22.
Eremina V, Jefferson JA, Kowalewska J, et al: VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129–1136.
23.
Murukesh N, Dive C, Jayson GC: Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 2010;102:8–18.
24.
Sutent (package insert). New York, Pfizer Labs, 2007.
25.
Nangaku M, Eckardt KU: Hypoxia and the HIF system in kidney disease. J Mol Med 2007;85:1325–1330.
26.
Khan G, Golshayan A, Elson P, et al: Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. Ann Oncol 2010;21:1618–1622.
27.
Zhu X, Stergiopoulos K, Wu S: Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009;48:9–17.
28.
Rixe O, Billemont B, Izzedine H: Hypertension as a predictive factor of sunitinib activity. Ann Oncol 2007;18:1117.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.